265 research outputs found

    The European Federation of Organisations for Medical Physics policy statement no 14 : the role of the medical physicist in the management of safety within the magnetic resonance imaging environment : EFOMP recommendations

    Get PDF
    This European Federation of Organisations for Medical Physics (EFOMP) Policy Statement outlines the way in which a Safety Management System can be developed for MRI units. The Policy Statement can help eliminate or at least minimize accidents or incidents in the magnetic resonance environment and is recommended as a step towards harmonisation of safety of workers, patients, and the general public regarding the use of magnetic resonance imaging systems in diagnostic and interventional procedures.peer-reviewe

    Spatial and temporal evolution of an experimental debris flow, exhibiting coupled fluid and particulate phases

    Get PDF
    The internal behaviour of debris flows provides fundamental insight into the mechanics responsible for their motion. We provide robust velocity data within a small-scale experimental debris flow, consisting of the instantaneous release of a granular material along a rectangular flume, inclined at 31∘. The results show a unique layered transition from a collisional, turbulent front to a non-fluctuating viscous-type flow body, exhibiting strong fluid-particulate coupling. This is the first time that the internal dynamics have been documented within the full architecture of a developing experimental debris flow, from the head to the tail

    The effect of Schmidt number on gravity current flows: The formation of large-scale three-dimensional structures

    Get PDF
    The Schmidt number, defined as the ratio of scalar to momentum diffusivity, varies by multiple orders of magnitude in real-world flows, with large differences in scalar diffusivity between temperature, solute, and sediment driven flows. This is especially crucial in gravity currents, where the flow dynamics may be driven by differences in temperature, solute, or sediment, and yet the effect of Schmidt number on the structure and dynamics of gravity currents is poorly understood. Existing numerical work has typically assumed a Schmidt number near unity, despite the impact of Schmidt number on the development of fine-scale flow structure. The few numerical investigations considering high Schmidt number gravity currents have relied heavily on two-dimensional simulations when discussing Schmidt number effects, leaving the effect of high Schmidt number on three-dimensional flow features unknown. In this paper, three-dimensional direct numerical simulations of constant-influx solute-based gravity currents with Reynolds numbers 100 ≤ R e ≤ 3000 and Schmidt number 1 are presented, with the effect of Schmidt number considered in cases with (R e, S c) = (100, 10), (100, 100), and (500, 10). These data are used to establish the effect of Schmidt number on different properties of gravity currents, such as density distribution and interface stability. It is shown that increasing Schmidt number from 1 leads to substantial structural changes not seen with increased Reynolds number in the range considered here. Recommendations are made regarding lower Schmidt number assumptions, usually made to reduce computational cost

    Numerical modelling of particle-laden sonic CO2 jets with experimental validation

    Get PDF
    The characteristics of the particle distribution, evolution and movement in a sonic jet release of carbon dioxide (CO2) from a high pressure reservoir are investigated. The motivation is to numerically model the sonic jet with particles, using the hitherto unknown initial particle distribution measured herein, and hence understand and numerically reproduce the experimentally observedparticle behaviour downstream of the Mach shock, including turbulence characteristics and level of agglomeration. We employ a Reynolds-averaged Navier-Stokes scheme with adaptive mesh refinement (AMR), combined with a Lagrangian particle tracker and particle distribution function. The model is seeded at the nozzle with the experimentally measured particle distribution and exploited to reproduce the observed characteristics of the jet. These releases are designed to be representative of a sonic CO2 release into the atmosphere and so provide data to help interpret how accidental or operational releases from the transport aspect of a carbon capture and storage chain might behave

    Differential activity and expression of human 5β-reductase (AKR1D1) splice variants

    Get PDF
    Steroid hormones, including glucocorticoids and androgens, exert a wide variety of effects in the body across almost all tissues. The steroid A-ring 5beta-reductase (AKR1D1) is expressed in human liver and testes, and three splice variants have been identified (AKR1D1-001, AKR1D1-002, AKR1D1-006). Amongst these, AKR1D1-002 is the best described; it modulates steroid hormone availability and catalyses an important step in bile acid biosynthesis. However, specific activity and expression of AKR1D1-001 and AKR1D1-006 are unknown. Expression of AKR1D1 variants were measured in human liver biopsies and hepatoma cell lines by qPCR. Their three-dimensional (3D) structures were predicted using in silico approaches. AKR1D1 variants were over-expressed in HEK293 cells, and successful overexpression confirmed by qPCR and western blotting. Cells were treated with either cortisol, dexamethasone, prednisolone, testosterone or androstenedione, and steroid hormone clearance was measured by mass spectrometry. Glucocorticoid and androgen receptor activation were determined by luciferase reporter assays. AKR1D1-002 and AKR1D1-001 are expressed in human liver, and only AKR1D1-006 is expressed in human testes. Following over-expression, AKR1D1-001 and AKR1D1-006 protein levels were lower than AKR1D1-002, but significantly increased following treatment with the proteasomal inhibitor, MG-132. AKR1D1-002 efficiently metabolised glucocorticoids and androgens and decreased receptor activation. AKR1D1-001 and AKR1D1-006 poorly metabolised dexamethasone, but neither protein metabolised cortisol, prednisolone, testosterone or androstenedione. We have demonstrated the differential expression and role of AKR1D1 variants in steroid hormone clearance and receptor activation in vitro. AKR1D1-002 is the predominant functional protein in steroidogenic and metabolic tissues. In addition, AKR1D1-001 and AKR1D1-006 may have a limited, steroid-specific role in the regulation of dexamethasone action

    The androgen receptor gene CAG repeat in relation to 4-year changes in androgen-sensitive endpoints in community-dwelling older European men

    Get PDF
    Context: The Androgen Receptor (AR) gene exon 1 CAG repeat length has been proposed to be a determinant of between-individual variations in androgen action in target tissues, which might regulate phenotypic differences of human ageing. However, findings on its phenotypic effects are inconclusive.Objective: To assess whether the AR CAG repeat length is associated with longitudinal changes in endpoints which are influenced by testosterone (T) levels in middle-aged and elderly European men.Design: Multinational European observational prospective cohort studyParticipants: 1887 men (mean±sd age: 63±11 years; median follow-up: 4.3 years) from centres of 8 European countries comprised the analysis sample after exclusion of those with diagnosed diseases of the hypothalamic-pituitary-testicular (HPT) axis.Main outcome measures: Longitudinal associations between the AR CAG repeat and changes in androgen-sensitive endpoints (ASEs) and medical conditions were assessed using regression analysis adjusting for age and centre. The AR CAG repeat length was treated both as a continuous and categorical (6-20; 21-23; 24-39 repeats) predictor. Additional analysis investigated whether results were independent of baseline T or oestradiol (E2) levels.Results: The AR CAG repeat, when used as a continuous or categorical predictor, was not associated with longitudinal changes in ASEs or medical conditions after adjustments. These results were independent of T and E2 levels.Conclusion: Within a 4-year timeframe, variations in the AR CAG repeat do not contribute to the rate of phenotypic ageing, over and above, that, which might be associated with the age-related decline in T levels

    Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism

    Get PDF
    BACKGROUND. Adrenal aldosterone excess is the most common cause of secondary hypertension and is associated with increased cardiovascular morbidity. However, adverse metabolic risk in primary aldosteronism extends beyond hypertension, with increased rates of insulin resistance, type 2 diabetes, and osteoporosis, which cannot be easily explained by aldosterone excess. METHODS. We performed mass spectrometry–based analysis of a 24-hour urine steroid metabolome in 174 newly diagnosed patients with primary aldosteronism (103 unilateral adenomas, 71 bilateral adrenal hyperplasias) in comparison to 162 healthy controls, 56 patients with endocrine inactive adrenal adenoma, 104 patients with mild subclinical, and 47 with clinically overt adrenal cortisol excess. We also analyzed the expression of cortisol-producing CYP11B1 and aldosterone-producing CYP11B2 enzymes in adenoma tissue from 57 patients with aldosterone-producing adenoma, employing immunohistochemistry with digital image analysis. RESULTS. Primary aldosteronism patients had significantly increased cortisol and total glucocorticoid metabolite excretion (all P < 0.001), only exceeded by glucocorticoid output in patients with clinically overt adrenal Cushing syndrome. Several surrogate parameters of metabolic risk correlated significantly with glucocorticoid but not mineralocorticoid output. Intratumoral CYP11B1 expression was significantly associated with the corresponding in vivo glucocorticoid excretion. Unilateral adrenalectomy resolved both mineralocorticoid and glucocorticoid excess. Postoperative evidence of adrenal insufficiency was found in 13 (29%) of 45 consecutively tested patients. CONCLUSION. Our data indicate that glucocorticoid cosecretion is frequently found in primary aldosteronism and contributes to associated metabolic risk. Mineralocorticoid receptor antagonist therapy alone may not be sufficient to counteract adverse metabolic risk in medically treated patients with primary aldosteronism

    Tissue Glucocorticoid Metabolism in Adrenal Insufficiency:A Prospective Study of Dual-release Hydrocortisone Therapy

    Get PDF
    Background: Patients with adrenal insufficiency (AI) require life-long glucocorticoid (GC) replacement therapy. Within tissues, cortisol (F) availability is under the control of the isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD). We hypothesize that corticosteroid metabolism is altered in patients with AI because of the nonphysiological pattern of current immediate release hydrocortisone (IR-HC) replacement therapy. The use of a once-daily dual-release hydrocortisone (DR-HC) preparation, (Plenadren®), offers a more physiological cortisol profile and may alter corticosteroid metabolism in vivo.Study Design and Methods: Prospective crossover study assessing the impact of 12 weeks of DR-HC on systemic GC metabolism (urinary steroid metabolome profiling), cortisol activation in the liver (cortisone acetate challenge test), and subcutaneous adipose tissue (microdialysis, biopsy for gene expression analysis) in 51 patients with AI (primary and secondary) in comparison to IR-HC treatment and age- and BMI-matched controls.Results: Patients with AI receiving IR-HC had a higher median 24-hour urinary excretion of cortisol compared with healthy controls (72.1 µg/24 hours [IQR 43.6-124.2] vs 51.9 µg/24 hours [35.5-72.3], P = .02), with lower global activity of 11β-HSD2 and higher 5-alpha reductase activity. Following the switch from IR-HC to DR-HC therapy, there was a significant reduction in urinary cortisol and total GC metabolite excretion, which was most significant in the evening. There was an increase in 11β-HSD2 activity. Hepatic 11β-HSD1 activity was not significantly altered after switching to DR-HC, but there was a significant reduction in the expression and activity of 11β-HSD1 in subcutaneous adipose tissue.Conclusion: Using comprehensive in vivo techniques, we have demonstrated abnormalities in corticosteroid metabolism in patients with primary and secondary AI receiving IR-HC. This dysregulation of pre-receptor glucocorticoid metabolism results in enhanced glucocorticoid activation in adipose tissue, which was ameliorated by treatment with DR-HC
    • …
    corecore